RecruitingPhase 3NCT05852990

Glutamine Plus L. Reuteri Prevents TKI Therapy-diarrhea in Patients With NSCLC

Effect of Glutamine Plus Lactobacillus Reuteri Added to an Astringent Diet in Preventing Diarrhea Caused by Tyrosine Kinase Inhibitors (TKIs) in Patients With Advanced Non-small Cell Lung Cancer


Sponsor

Instituto Nacional de Cancerologia de Mexico

Enrollment

28 participants

Start Date

Mar 1, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

This open-label randomized clinical trial aims to evaluate the glutamine plus Lactobacillus reuteri supplementation effect in a standard-of-care diet in EGFR mutant patients with advanced non-small cell lung cancer (NSCLC) under tyrosine kinase inhibitors (TKIs) therapy. The main question it aims to answer is ¿What is the effect of glutamine plus L. reuteri added to an astringent diet in preventing diarrhea generated by TKI therapy? Patients will receive an astringent diet supplemented with 10 grams of glutamine and L. reuteri (100 million CFU). Researchers will compare the Glutamine plus L. reuteri diet with a standard astringent diet to see if TKI therapy diarrhea is prevented.


Eligibility

Min Age: 18 YearsMax Age: 80 Years

Inclusion Criteria8

  • Both sexes
  • ≥ 18 years old
  • Pathologically confirmed diagnosis of NSCLC
  • Stage IIIB - IV by the American Joint Committee of Cancer Version 8.
  • Candidates to receive EGFR-TKI treatment (1st \& 2nd generation TKI)
  • ECOG score ≤ 2
  • Life expectancy \> eight weeks
  • Signed written informed consent

Exclusion Criteria7

  • Patients who cannot attend the first protocol appointment.
  • Treatment with other anti-cancer therapy
  • Participating in other clinical trials in the former four weeks
  • Any other serious condition or uncontrolled active infection, altered mental status or psychiatric disorder that, in the investigator´s opinion, would limit the ability of an individual to meet the requirements of the study or which affects the interpretability of the results.
  • Active hepatitis virus infection (any serotype) or chronic infection with a potential risk of reactivation evaluated through a serological panel.
  • Active HIV infection.
  • Breastfeeding.

Interventions

COMBINATION_PRODUCTGlutamine plus L. reuteri

Glutamine plus Lactobacillus reueri twice daily for up to 6 weeks or death


Locations(1)

Instituto Nacional de Cancerologia de Mexico

Mexico City, Mexico

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05852990


Related Trials